Stockreport

ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That...

ChromaDex Corporation  (CDXC) 
NASDAQ:AMEX Investor Relations: investors.chromadex.com
PDF Preclinical research from Dr. Charles Brenner and a team of leading scientists from three US universities concludes that key steps in coronavirus infection and innate im [Read more]